Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 121

1.

HDAC11 suppresses the thermogenic program of adipose tissue via BRD2.

Bagchi RA, Ferguson BS, Stratton MS, Hu T, Cavasin MA, Sun L, Lin YH, Liu D, Londono P, Song K, Pino MF, Sparks LM, Smith SR, Scherer PE, Collins S, Seto E, McKinsey TA.

JCI Insight. 2018 Aug 9;3(15). pii: 120159. doi: 10.1172/jci.insight.120159. [Epub ahead of print]

2.

Histone deacetylase activity governs diastolic dysfunction through a nongenomic mechanism.

Jeong MY, Lin YH, Wennersten SA, Demos-Davies KM, Cavasin MA, Mahaffey JH, Monzani V, Saripalli C, Mascagni P, Reece TB, Ambardekar AV, Granzier HL, Dinarello CA, McKinsey TA.

Sci Transl Med. 2018 Feb 7;10(427). pii: eaao0144. doi: 10.1126/scitranslmed.aao0144.

3.

DUSP5 functions as a feedback regulator of TNFα-induced ERK1/2 dephosphorylation and inflammatory gene expression in adipocytes.

Habibian JS, Jefic M, Bagchi RA, Lane RH, McKnight RA, McKinsey TA, Morrison RF, Ferguson BS.

Sci Rep. 2017 Oct 10;7(1):12879. doi: 10.1038/s41598-017-12861-y.

4.

Class I HDACs control a JIP1-dependent pathway for kinesin-microtubule binding in cardiomyocytes.

Blakeslee WW, Lin YH, Stratton MS, Tatman PD, Hu T, Ferguson BS, McKinsey TA.

J Mol Cell Cardiol. 2017 Nov;112:74-82. doi: 10.1016/j.yjmcc.2017.09.002. Epub 2017 Sep 5.

5.

p38α: A Profibrotic Signaling Nexus.

Stratton MS, Koch KA, McKinsey TA.

Circulation. 2017 Aug 8;136(6):562-565. doi: 10.1161/CIRCULATIONAHA.117.028957. No abstract available.

6.

BRD4 inhibition for the treatment of pathological organ fibrosis.

Stratton MS, Haldar SM, McKinsey TA.

F1000Res. 2017 Jun 28;6. pii: F1000 Faculty Rev-1015. doi: 10.12688/f1000research.11339.1. eCollection 2017. Review.

7.

Histone deacetylase adaptation in single ventricle heart disease and a young animal model of right ventricular hypertrophy.

Blakeslee WW, Demos-Davies KM, Lemon DD, Lutter KM, Cavasin MA, Payne S, Nunley K, Long CS, McKinsey TA, Miyamoto SD.

Pediatr Res. 2017 Oct;82(4):642-649. doi: 10.1038/pr.2017.126. Epub 2017 Jun 21.

8.

BET bromodomain inhibition suppresses innate inflammatory and profibrotic transcriptional networks in heart failure.

Duan Q, McMahon S, Anand P, Shah H, Thomas S, Salunga HT, Huang Y, Zhang R, Sahadevan A, Lemieux ME, Brown JD, Srivastava D, Bradner JE, McKinsey TA, Haldar SM.

Sci Transl Med. 2017 May 17;9(390). pii: eaah5084. doi: 10.1126/scitranslmed.aah5084.

9.

Imaging cardiac SCN5A using the novel F-18 radiotracer radiocaine.

Hooker JM, Strebl MG, Schroeder FA, Wey HY, Ambardekar AV, McKinsey TA, Schoenberger M.

Sci Rep. 2017 Feb 16;7:42136. doi: 10.1038/srep42136.

10.

Overlapping and Divergent Actions of Structurally Distinct Histone Deacetylase Inhibitors in Cardiac Fibroblasts.

Schuetze KB, Stratton MS, Blakeslee WW, Wempe MF, Wagner FF, Holson EB, Kuo YM, Andrews AJ, Gilbert TM, Hooker JM, McKinsey TA.

J Pharmacol Exp Ther. 2017 Apr;361(1):140-150. doi: 10.1124/jpet.116.237701. Epub 2017 Feb 7.

11.

Interleukin-37 suppresses the osteogenic responses of human aortic valve interstitial cells in vitro and alleviates valve lesions in mice.

Zeng Q, Song R, Fullerton DA, Ao L, Zhai Y, Li S, Ballak DB, Cleveland JC Jr, Reece TB, McKinsey TA, Xu D, Dinarello CA, Meng X.

Proc Natl Acad Sci U S A. 2017 Feb 14;114(7):1631-1636. doi: 10.1073/pnas.1619667114. Epub 2017 Jan 30.

12.

Tryptophan hydroxylase 1 Inhibition Impacts Pulmonary Vascular Remodeling in Two Rat Models of Pulmonary Hypertension.

Aiello RJ, Bourassa PA, Zhang Q, Dubins J, Goldberg DR, De Lombaert S, Humbert M, Guignabert C, Cavasin MA, McKinsey TA, Paralkar V.

J Pharmacol Exp Ther. 2017 Feb;360(2):267-279. doi: 10.1124/jpet.116.237933. Epub 2016 Dec 7.

13.

The potential of targeting epigenetic regulators for the treatment of fibrotic cardiac diseases.

Schuetze KB, Koch KA, McKinsey TA.

Future Med Chem. 2016 Sep;8(13):1533-6. doi: 10.4155/fmc-2016-0144. Epub 2016 Aug 24. No abstract available.

14.

Histone deacetylase 3 regulates the inflammatory gene expression programme of rheumatoid arthritis fibroblast-like synoviocytes.

Angiolilli C, Kabala PA, Grabiec AM, Van Baarsen IM, Ferguson BS, García S, Malvar Fernandez B, McKinsey TA, Tak PP, Fossati G, Mascagni P, Baeten DL, Reedquist KA.

Ann Rheum Dis. 2017 Jan;76(1):277-285. doi: 10.1136/annrheumdis-2015-209064. Epub 2016 Jul 25.

15.

Signal-Dependent Recruitment of BRD4 to Cardiomyocyte Super-Enhancers Is Suppressed by a MicroRNA.

Stratton MS, Lin CY, Anand P, Tatman PD, Ferguson BS, Wickers ST, Ambardekar AV, Sucharov CC, Bradner JE, Haldar SM, McKinsey TA.

Cell Rep. 2016 Aug 2;16(5):1366-1378. doi: 10.1016/j.celrep.2016.06.074. Epub 2016 Jul 14.

16.

Histone deacetylation contributes to low extracellular superoxide dismutase expression in human idiopathic pulmonary arterial hypertension.

Nozik-Grayck E, Woods C, Stearman RS, Venkataraman S, Ferguson BS, Swain K, Bowler RP, Geraci MW, Ihida-Stansbury K, Stenmark KR, McKinsey TA, Domann FE.

Am J Physiol Lung Cell Mol Physiol. 2016 Jul 1;311(1):L124-34. doi: 10.1152/ajplung.00263.2015. Epub 2016 May 27.

17.

Myofibril growth during cardiac hypertrophy is regulated through dual phosphorylation and acetylation of the actin capping protein CapZ.

Lin YH, Warren CM, Li J, McKinsey TA, Russell B.

Cell Signal. 2016 Aug;28(8):1015-24. doi: 10.1016/j.cellsig.2016.05.011. Epub 2016 May 13.

18.

Discovery of novel small molecule inhibitors of cardiac hypertrophy using high throughput, high content imaging.

Reid BG, Stratton MS, Bowers S, Cavasin MA, Demos-Davies KM, Susano I, McKinsey TA.

J Mol Cell Cardiol. 2016 Aug;97:106-13. doi: 10.1016/j.yjmcc.2016.04.015. Epub 2016 Apr 27.

19.

Nuclear PTEN functions as an essential regulator of SRF-dependent transcription to control smooth muscle differentiation.

Horita H, Wysoczynski CL, Walker LA, Moulton KS, Li M, Ostriker A, Tucker R, McKinsey TA, Churchill ME, Nemenoff RA, Weiser-Evans MC.

Nat Commun. 2016 Mar 4;7:10830. doi: 10.1038/ncomms10830.

20.

Epigenetic regulation of cardiac fibrosis.

Stratton MS, McKinsey TA.

J Mol Cell Cardiol. 2016 Mar;92:206-13. doi: 10.1016/j.yjmcc.2016.02.011. Epub 2016 Feb 12. Review.

21.

High-efficiency reprogramming of fibroblasts into cardiomyocytes requires suppression of pro-fibrotic signalling.

Zhao Y, Londono P, Cao Y, Sharpe EJ, Proenza C, O'Rourke R, Jones KL, Jeong MY, Walker LA, Buttrick PM, McKinsey TA, Song K.

Nat Commun. 2015 Sep 10;6:8243. doi: 10.1038/ncomms9243.

22.

TNAP: a new player in cardiac fibrosis? Focus on "Tissue-nonspecific alkaline phosphatase as a target of sFRP2 in cardiac fibroblasts".

Schuetze KB, McKinsey TA.

Am J Physiol Cell Physiol. 2015 Aug 1;309(3):C137-8. doi: 10.1152/ajpcell.00167.2015. Epub 2015 Jun 24. No abstract available.

23.

Emerging roles for histone deacetylases in pulmonary hypertension and right ventricular remodeling (2013 Grover Conference series).

Cavasin MA, Stenmark KR, McKinsey TA.

Pulm Circ. 2015 Mar;5(1):63-72. doi: 10.1086/679700. Review.

24.

Transgenic over-expression of YY1 induces pathologic cardiac hypertrophy in a sex-specific manner.

Stauffer BL, Dockstader K, Russell G, Hijmans J, Walker L, Cecil M, Demos-Davies K, Medway A, McKinsey TA, Sucharov CC.

Biochem Biophys Res Commun. 2015 Jun 26;462(2):131-7. doi: 10.1016/j.bbrc.2015.04.106. Epub 2015 Apr 29.

25.

Novel Interaction of Class IIb Histone Deacetylase 6 (HDAC6) with Class IIa HDAC9 Controls Gonadotropin Releasing Hormone (GnRH) Neuronal Cell Survival and Movement.

Salian-Mehta S, Xu M, McKinsey TA, Tobet S, Wierman ME.

J Biol Chem. 2015 May 29;290(22):14045-56. doi: 10.1074/jbc.M115.640482. Epub 2015 Apr 14.

26.

Promiscuous actions of small molecule inhibitors of the protein kinase D-class IIa HDAC axis in striated muscle.

Lemon DD, Harrison BC, Horn TR, Stratton MS, Ferguson BS, Wempe MF, McKinsey TA.

FEBS Lett. 2015 Apr 28;589(10):1080-8. doi: 10.1016/j.febslet.2015.03.017. Epub 2015 Mar 25.

27.

Non-sirtuin histone deacetylases in the control of cardiac aging.

Ferguson BS, McKinsey TA.

J Mol Cell Cardiol. 2015 Jun;83:14-20. doi: 10.1016/j.yjmcc.2015.03.010. Epub 2015 Mar 16. Review.

28.

Acetyl-lysine erasers and readers in the control of pulmonary hypertension and right ventricular hypertrophy.

Stratton MS, McKinsey TA.

Biochem Cell Biol. 2015 Apr;93(2):149-57. doi: 10.1139/bcb-2014-0119. Epub 2014 Dec 16. Review.

29.

AKT network of genes and impaired myocardial contractility during murine acute Chagasic myocarditis.

Henao-Martínez AF, Agler AH, Watson AM, Hennessy C, Davidson E, Demos-Davies K, McKinsey TA, Wilson M, Schwartz DA, Yang IV.

Am J Trop Med Hyg. 2015 Mar;92(3):523-9. doi: 10.4269/ajtmh.14-0433. Epub 2015 Jan 12.

30.

Inflammatory cytokines epigenetically regulate rheumatoid arthritis fibroblast-like synoviocyte activation by suppressing HDAC5 expression.

Angiolilli C, Grabiec AM, Ferguson BS, Ospelt C, Malvar Fernandez B, van Es IE, van Baarsen LG, Gay S, McKinsey TA, Tak PP, Baeten DL, Reedquist KA.

Ann Rheum Dis. 2016 Feb;75(2):430-8. doi: 10.1136/annrheumdis-2014-205635. Epub 2014 Dec 1.

31.

Reversal of severe angioproliferative pulmonary arterial hypertension and right ventricular hypertrophy by combined phosphodiesterase-5 and endothelin receptor inhibition.

Cavasin MA, Demos-Davies KM, Schuetze KB, Blakeslee WW, Stratton MS, Tuder RM, McKinsey TA.

J Transl Med. 2014 Nov 26;12:314. doi: 10.1186/s12967-014-0314-y.

32.

Tubulin hyperacetylation is adaptive in cardiac proteotoxicity by promoting autophagy.

McLendon PM, Ferguson BS, Osinska H, Bhuiyan MS, James J, McKinsey TA, Robbins J.

Proc Natl Acad Sci U S A. 2014 Dec 2;111(48):E5178-86. doi: 10.1073/pnas.1415589111. Epub 2014 Nov 17.

33.

Diet and sex modify exercise and cardiac adaptation in the mouse.

Konhilas JP, Chen H, Luczak E, McKee LA, Regan J, Watson PA, Stauffer BL, Khalpey ZI, Mckinsey TA, Horn T, LaFleur B, Leinwand LA.

Am J Physiol Heart Circ Physiol. 2015 Jan 15;308(2):H135-45. doi: 10.1152/ajpheart.00532.2014. Epub 2014 Nov 14.

34.

Class I HDAC inhibition stimulates cardiac protein SUMOylation through a post-translational mechanism.

Blakeslee WW, Wysoczynski CL, Fritz KS, Nyborg JK, Churchill ME, McKinsey TA.

Cell Signal. 2014 Dec;26(12):2912-20. doi: 10.1016/j.cellsig.2014.09.005. Epub 2014 Sep 16.

35.

Endoplasmic reticulum stress effector CCAAT/enhancer-binding protein homologous protein (CHOP) regulates chronic kidney disease-induced vascular calcification.

Miyazaki-Anzai S, Masuda M, Demos-Davies KM, Keenan AL, Saunders SJ, Masuda R, Jablonski K, Cavasin MA, Kendrick J, Chonchol M, McKinsey TA, Levi M, Miyazaki M.

J Am Heart Assoc. 2014 Jun 24;3(3):e000949. doi: 10.1161/JAHA.114.000949.

36.

HDAC6 contributes to pathological responses of heart and skeletal muscle to chronic angiotensin-II signaling.

Demos-Davies KM, Ferguson BS, Cavasin MA, Mahaffey JH, Williams SM, Spiltoir JI, Schuetze KB, Horn TR, Chen B, Ferrara C, Scellini B, Piroddi N, Tesi C, Poggesi C, Jeong MY, McKinsey TA.

Am J Physiol Heart Circ Physiol. 2014 Jul 15;307(2):H252-8. doi: 10.1152/ajpheart.00149.2014. Epub 2014 May 23.

37.

BET-ting on chromatin-based therapeutics for heart failure.

Haldar SM, McKinsey TA.

J Mol Cell Cardiol. 2014 Sep;74:98-102. doi: 10.1016/j.yjmcc.2014.05.002. Epub 2014 May 14. Review.

38.

Targeting cardiac fibroblasts to treat fibrosis of the heart: focus on HDACs.

Schuetze KB, McKinsey TA, Long CS.

J Mol Cell Cardiol. 2014 May;70:100-7. doi: 10.1016/j.yjmcc.2014.02.015. Epub 2014 Mar 11. Review.

39.

Class I HDACs regulate angiotensin II-dependent cardiac fibrosis via fibroblasts and circulating fibrocytes.

Williams SM, Golden-Mason L, Ferguson BS, Schuetze KB, Cavasin MA, Demos-Davies K, Yeager ME, Stenmark KR, McKinsey TA.

J Mol Cell Cardiol. 2014 Feb;67:112-25. doi: 10.1016/j.yjmcc.2013.12.013. Epub 2013 Dec 26.

40.

Estrogen regulates histone deacetylases to prevent cardiac hypertrophy.

Pedram A, Razandi M, Narayanan R, Dalton JT, McKinsey TA, Levin ER.

Mol Biol Cell. 2013 Dec;24(24):3805-18. doi: 10.1091/mbc.E13-08-0444. Epub 2013 Oct 23.

41.

MicroRNA-124 controls the proliferative, migratory, and inflammatory phenotype of pulmonary vascular fibroblasts.

Wang D, Zhang H, Li M, Frid MG, Flockton AR, McKeon BA, Yeager ME, Fini MA, Morrell NW, Pullamsetti SS, Velegala S, Seeger W, McKinsey TA, Sucharov CC, Stenmark KR.

Circ Res. 2014 Jan 3;114(1):67-78. doi: 10.1161/CIRCRESAHA.114.301633. Epub 2013 Oct 11.

42.

BET acetyl-lysine binding proteins control pathological cardiac hypertrophy.

Spiltoir JI, Stratton MS, Cavasin MA, Demos-Davies K, Reid BG, Qi J, Bradner JE, McKinsey TA.

J Mol Cell Cardiol. 2013 Oct;63:175-9. doi: 10.1016/j.yjmcc.2013.07.017. Epub 2013 Aug 9.

43.

Signal-dependent repression of DUSP5 by class I HDACs controls nuclear ERK activity and cardiomyocyte hypertrophy.

Ferguson BS, Harrison BC, Jeong MY, Reid BG, Wempe MF, Wagner FF, Holson EB, McKinsey TA.

Proc Natl Acad Sci U S A. 2013 Jun 11;110(24):9806-11. doi: 10.1073/pnas.1301509110. Epub 2013 May 29.

44.

Response to letter regarding article, “histone deacetylation inhibition in pulmonary hypertension: therapeutic potential of valproic acid and suberoylanilide hydroxamic acid”.

Zhao L, Chen CN, Hajji N, Oliver E, Cotroneo E, Wharton J, Wilkins MR, Wang D, Li M, Stenmark KR, McKinsey TA, Buttrick P.

Circulation. 2013 Apr 9;127(14):e540. No abstract available.

PMID:
23691553
45.

Hypoxia alters ocular drug transporter expression and activity in rat and calf models: implications for drug delivery.

Kadam RS, Ramamoorthy P, LaFlamme DJ, McKinsey TA, Kompella UB.

Mol Pharm. 2013 Jun 3;10(6):2350-61. doi: 10.1021/mp3007133. Epub 2013 May 22. Retraction in: Mol Pharm. 2015 Jul 6;12(7):2559.

46.

Roles of histone deacetylation and AMP kinase in regulation of cardiomyocyte PGC-1α gene expression in hypoxia.

Ramjiawan A, Bagchi RA, Blant A, Albak L, Cavasin MA, Horn TR, McKinsey TA, Czubryt MP.

Am J Physiol Cell Physiol. 2013 Jun 1;304(11):C1064-72. doi: 10.1152/ajpcell.00262.2012. Epub 2013 Mar 20.

47.

Histone deacetylation inhibition in pulmonary hypertension: therapeutic potential of valproic acid and suberoylanilide hydroxamic acid.

Zhao L, Chen CN, Hajji N, Oliver E, Cotroneo E, Wharton J, Wang D, Li M, McKinsey TA, Stenmark KR, Wilkins MR.

Circulation. 2012 Jul 24;126(4):455-67. doi: 10.1161/CIRCULATIONAHA.112.103176. Epub 2012 Jun 18.

48.

Selective class I histone deacetylase inhibition suppresses hypoxia-induced cardiopulmonary remodeling through an antiproliferative mechanism.

Cavasin MA, Demos-Davies K, Horn TR, Walker LA, Lemon DD, Birdsey N, Weiser-Evans MC, Harral J, Irwin DC, Anwar A, Yeager ME, Li M, Watson PA, Nemenoff RA, Buttrick PM, Stenmark KR, McKinsey TA.

Circ Res. 2012 Mar 2;110(5):739-48. doi: 10.1161/CIRCRESAHA.111.258426. Epub 2012 Jan 26.

49.

Therapeutic potential for HDAC inhibitors in the heart.

McKinsey TA.

Annu Rev Pharmacol Toxicol. 2012;52:303-19. doi: 10.1146/annurev-pharmtox-010611-134712. Epub 2011 Sep 26. Review.

PMID:
21942627
50.

The biology and therapeutic implications of HDACs in the heart.

McKinsey TA.

Handb Exp Pharmacol. 2011;206:57-78. doi: 10.1007/978-3-642-21631-2_4. Review.

PMID:
21879446

Supplemental Content

Loading ...
Support Center